Stoke/Biogen present zorevunersen Phase 3 EMPEROR analysis showing cognition/behavior improvements at Week 68

Stoke Therapeutics, Inc.

Analysis of patients on EMPEROR-like regimen (2x70mg loading + 2x45mg maintenance) showed cognition/behavior improvements at Week 68.
Results contrast with natural history (BUTTERFLY) where standard-of-care patients did not show improvements.
Five Vineland-3 sub-domains (Receptive/Expressive Communication, Interpersonal Relationships, Coping/Personal Skills) added as key secondary endpoints in Phase 3 EMPEROR.
Data complement prior Phase 1/2a and OLE results showing durable seizure reductions and improvements through two years.
Zorevunersen is a first-in-class potential disease-modifying RNA medicine for Dravet syndrome co-developed with Biogen.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.